Sol-Gel Technologies Ltd. (SLGL) stock
SLGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 19, 2026Score 10/30
$55.12−1.13 (-2.01%)
Close on Nov 13, 2026Market cap $153.57MP/E –Yield –
Sol-Gel Technologies EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$2.19. The highest annual figure on record is $50.20 in fiscal 2017.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.19 | – |
| FY2024 | Dec 31, 2024 | -$3.79 | – |
| FY2023 | Dec 31, 2023 | -$10.01 | – |
| FY2022 | Dec 31, 2022 | -$6.50 | -564.3% |
| FY2021 | Dec 31, 2021 | $1.40 | – |
| FY2020 | Dec 31, 2020 | -$13.00 | – |
| FY2019 | Dec 31, 2019 | -$12.60 | -170.0% |
| FY2018 | Dec 31, 2018 | $18.00 | -64.1% |
| FY2017 | Dec 31, 2017 | $50.20 | +52.1% |
| FY2016 | Dec 31, 2016 | $33.00 | +115.7% |
| FY2015 | Dec 31, 2015 | $15.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.13 | -1230.0% |
| Q2 FY2025 | Jun 30, 2025 | $4.17 | +19.1% |
| Q2 FY2024 | Jun 30, 2024 | $0.71 | -77.1% |
| Q2 FY2023 | Jun 30, 2023 | -$2.20 | -184.6% |
| Q2 FY2022 | Jun 30, 2022 | $0.10 | -97.2% |
| Q2 FY2021 | Jun 30, 2021 | $3.50 | – |
| Q2 FY2020 | Jun 30, 2020 | $3.10 | – |
| Q2 FY2019 | Jun 30, 2019 | $2.60 | – |
| Q2 FY2018 | Jun 30, 2018 | $3.60 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?